{
    "organizations": [],
    "uuid": "6256aee28a2216a830aafcf56f57331bd51c885d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-vistagen-therapeutics-receives-us/brief-vistagen-therapeutics-receives-u-s-patent-covering-oral-formulations-of-av-101-idUSFWN1R10RB",
    "ord_in_thread": 0,
    "title": "BRIEF-Vistagen Therapeutics Receives U.S. Patent Covering Oral Formulations Of Av-101",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 19, 2018 / 3:44 PM / Updated 13 minutes ago BRIEF-Vistagen Therapeutics Receives U.S. Patent Covering Oral Formulations Of Av-101 Reuters Staff 1 Min Read March 19 (Reuters) - Vistagen Therapeutics Inc: * VISTAGEN THERAPEUTICS RECEIVES A NOTICE OF ALLOWANCE FOR ANOTHER KEY U.S. PATENT COVERING ORAL FORMULATIONS OF AV-101  ",
    "published": "2018-03-19T17:43:00.000+02:00",
    "crawled": "2018-03-19T18:04:13.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "receives",
        "patent",
        "covering",
        "oral",
        "formulation",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "vistagen",
        "therapeutic",
        "inc",
        "vistagen",
        "therapeutic",
        "receives",
        "notice",
        "allowance",
        "another",
        "key",
        "patent",
        "covering",
        "oral",
        "formulation"
    ]
}